Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 14/20 | 0.44 |
| ▸ | HSP90B1 | P14625 | 8/20 | 0.44 |
| ▸ | HSP90AB1 | P08238 | 2/20 | 0.42 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5776909 | 0.85 | HSP90AA1 (0.44) | HSP90AA1HSP90B1HSP90AB1MAPTPDGFRB | |
| SCHEMBL5777572 | 0.84 | HSP90AA1 (0.41) | HSP90AA1HSP90B1HSP90AB1ENPP2MAPT | |
| SCHEMBL5774191 | 0.83 | HSP90AA1 (0.45) | HSP90AA1HSP90B1PDGFRB | |
| SCHEMBL30405316 | 0.83 | HSP90AA1 (0.42) | HSP90AA1HSP90B1HSP90AB1ENPP2MAPT | |
| SCHEMBL28907586 | 0.83 | HSP90AA1 (0.42) | HSP90AA1HSP90B1HSP90AB1ENPP2MAPT | |
| SCHEMBL785547 | 0.80 | HSP90AA1 (0.59) | HSP90AA1HSP90B1HSP90AB1ENPP2MAPT | |
| SCHEMBL5775559 | 0.80 | HSP90AA1 (0.49) | HSP90AA1HSP90B1HSP90AB1MAPTPDGFRB | |
| SCHEMBL5776735 | 0.80 | HSP90AA1 (0.43) | HSP90AA1HSP90B1HSP90AB1ENPP2MAPT | |
| SCHEMBL5774769 | 0.79 | HSP90AA1 (0.43) | HSP90AA1HSP90B1HSP90AB1ENPP2MAPT | |
| SCHEMBL28745179 | 0.79 | HTR2C (0.54) | HSP90AB1ENPP2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | HSP90AA1 1452/4885HSP90B1 2333/4885HSP90AB1 1561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.